AquaBounty Technologies Q3 2026 Earnings Results & Report

AquaBounty Technologies EPS Results

• Actual EPS: -$0.23
• Consensus EPS: -$1.30
• Beat/Miss: Beat by +$1.07
• One Year Ago EPS: N/A
• EPS Beat Rate: 3 of last 8 quarters

AquaBounty Technologies Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $265 thousand
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

AquaBounty Technologies (NASDAQ:AQB) is a biotechnology and aquaculture company focused on developing and producing land-raised Atlantic salmon. Its principal product is AquAdvantage salmon, a genetically engineered salmon designed to reach market size more quickly than conventional Atlantic salmon. The company has pursued land-based, contained aquaculture systems intended to reduce reliance on ocean-based farming and improve production efficiency.

AquAdvantage salmon incorporates a growth-hormone gene from Chinook salmon and a regulatory sequence from ocean pout. The U.S. Food and Drug Administration approved the product for production, sale and consumption in the United States in 2015, making it the first genetically engineered animal approved for use as food in the country. Canadian authorities subsequently authorized its production and sale in Canada.

Founded in 1991, AquaBounty has historically operated research, broodstock and production activities in the United States and Canada. The company has focused on developing recirculating aquaculture systems and commercial-scale farms while working through the regulatory and operational requirements associated with producing genetically engineered seafood. Its activities and strategy have evolved as it has evaluated the commercial development of land-based salmon farming.